<SEC-DOCUMENT>0001564590-15-010821.txt : 20151116
<SEC-HEADER>0001564590-15-010821.hdr.sgml : 20151116
<ACCEPTANCE-DATETIME>20151116163910
ACCESSION NUMBER:		0001564590-15-010821
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20151116
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151116
DATE AS OF CHANGE:		20151116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cerulean Pharma Inc.
		CENTRAL INDEX KEY:			0001401914
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36395
		FILM NUMBER:		151235694

	BUSINESS ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		STREET 2:		5TH FLOOR
		CITY:			Cambridge
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-551-9600

	MAIL ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		STREET 2:		5TH FLOOR
		CITY:			Cambridge
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tempo Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070604
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ceru-8k_20151116.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ceru-8k_20151116.htm
</title>
</head>
<!-- NG Converter v4.0.2.6 -->
<body>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): November 16, 2015 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERULEAN PHARMA INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Delaware</font></p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">001-36395</font></p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">20-4139823</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">840 Memorial Drive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">02139</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (617) 551-9600 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings';"><font style="font-size:10pt;font-family:'Wingdings'">&#168;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><br></p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.02. Results of Operations and Financial Condition.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 16, 2015, Cerulean Pharma Inc. (the &#8220;Company&#8221;) issued a press release announcing, among other things, the Company&#8217;s operational highlights for the three and nine months ended September 30, 2015 and anticipated corporate and clinical milestones for the remainder of 2015 and 2016.&nbsp;&nbsp;A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information provided under Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-0.83%;width:98.01%;">
<tr>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;</p></td>
<td colspan="5" valign="top"  style="width:99.8%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits </p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:8.38%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom"  style="width:2.7%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:86.74%;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:89.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.38%;white-space:nowrap;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;99.1</p></td>
<td valign="bottom"  style="width:2.7%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:86.74%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press release dated November 16, 2015. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:3.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:2.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CERULEAN PHARMA INC.</p></td>
</tr>
<tr>
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:17.1pt;">
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 16, 2015</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Christopher D.T. Guiffre</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.86%;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher D.T. Guiffre</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press release dated November 16, 2015.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ceru-ex991_16.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ceru-ex991_16.htm
</title>
</head>
<!-- NG Converter v4.0.2.6 -->
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201511161930512845969.jpg" title="" alt="" style="width:314px;height:59px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Conference Call Today at 4:30 p.m.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CAMBRIDGE, Mass., November 16, 2015<font style="font-weight:normal;"> &#8211; </font><font style="text-decoration:underline;font-weight:normal;">Cerulean Pharma Inc.</font><font style="font-weight:normal;"> (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended September 30, 2015.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;During the third quarter, we strengthened our management team by appointing Adrian Senderowicz as Chief Medical Officer.&nbsp;&nbsp;Adrian&#8217;s experience in the lab and clinic at NCI, as a team leader at FDA, in clinical development at AstraZeneca, leading the oncology regulatory group at Sanofi, as CMO of Tokai and Ignyta, and as a board member of Puma Biotechnology make him well suited to lead our NDCs toward registration,&#8221; said Christopher D. T. Guiffre, President &amp; Chief Executive Officer of Cerulean.  &#8220;We also strengthened our Board of Directors by adding David Walt.&nbsp;&nbsp;David&#8217;s scientific acumen and entrepreneurial experience will be important to us as we expand our pipeline of platform-generated NDCs.  Our Dynamic Tumor Targeting&#8482; Platform continues to deliver results, and we just presented data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics proving our mechanism of action in humans for the first time.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third Quarter 2015 Corporate Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Clinical Data</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported first patient dosed in Phase 1b trial with the GOG Foundation, Inc. of CRLX101 in combination with weekly paclitaxel in patients with relapsed ovarian cancer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Data from this trial are expected in H1 2016, allowing Cerulean to compare results from this combination with results from an ongoing investigator-sponsored trial (IST) of CRLX101 in combination with Avastin<sup style="font-size:85%; vertical-align:top">&#174;</sup> (bevacizumab) in order to determine registration strategy for CRLX101 in relapsed ovarian cancer, an indication for which FDA has granted CRLX101 Orphan Drug Designation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported CRLX101 in combination with Avastin met a pre-determined stage gate in a Phase 2 IST in patients with relapsed ovarian cancer and advanced to Stage 2 of the trial</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Data from this trial show that the combination is active and generally well- tolerated and could represent an important new option for patients in an area of high unmet need, allowing Cerulean to consider this combination as one option for registration in relapsed ovarian cancer</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Teambuilding</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Appointed Adrian Senderowicz, M.D., as Senior Vice President and Chief Medical Officer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Appointed David R. Walt, Ph.D., University Professor, Robinson Professor of Chemistry, Professor of Biomedical Engineering, Professor of Genetics, Professor of Oral Medicine at Tufts University and Howard Hughes Medical Institute Professor, to Board of Directors</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Key Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CRLX101 Clinical Data</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Presented final results of Phase 1b/2 IST of CRLX101 in combination with Avastin in relapsed renal cell carcinoma (RCC) at 14<sup style="font-size:85%; vertical-align:top">th</sup> International Kidney Cancer Symposium</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Data from this trial led to launch of randomized Phase 2 trial in relapsed RCC</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">Presented evidence of selective accumulation of CRLX101 in tumors versus healthy tissue and inhibition of CRLX101&#8217;s molecular targets in tumor cells at 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;color:#000000;">These data represent first proof of mechanism in humans for Cerulean&#8217;s Dynamic Tumor Targeting Platform</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported interim data from 18 patients enrolled in Stage 1 of ongoing Phase 2 IST of CRLX101 in combination with Avastin in relapsed ovarian cancer</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investigator-reported activity data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">9 of 16 (56%) patients evaluable for progression free survival (PFS) at six months achieved at least six months PFS, exceeding the 20% rate expected in this setting</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">3 of 17 (18%) patients evaluable for overall response rate (ORR) achieved a partial response under RECIST criteria</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">14 of 17 (82%) patients evaluable for ORR achieved stable disease under RECIST criteria</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">8 of 18 (44%) patients evaluable for CA 125 levels achieved at least 50% decrease in CA 125, a blood biomarker used to monitor ovarian cancer activity</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investigator-reported tolerability data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">No dose limiting toxicities (DLTs); combination appears to be generally well- tolerated</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Next steps:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Enroll an additional 25 patients in Stage 2</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Consider CRLX101-Avastin combination as one registration option in relapsed ovarian cancer</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported interim data from 22 evaluable patients in ongoing Phase 1b/2 IST of CRLX101 in combination with chemoradiotherapy in locally advanced rectal cancer</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investigator-reported activity data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">4 of 22 patients (18%) achieved a pathological complete response (pCR), which represents an AJCC/UICC tumor regression grading of 0 on a scale of 0 to 3</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">8 of 22 patients (36%) achieved minimal residual disease, which represents an AJCC/UICC tumor regression grading of 1 on a scale of 0 to 3</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investigator-reported tolerability data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">No DLTs; combination appears to be generally well-tolerated</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Next steps:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Enroll an additional 53 patients using weekly dosing schedule</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">If weekly dosing schedule significantly increases pCR rates, discuss with FDA the possibility of using pCR as an approval endpoint</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="text-decoration:underline;">C</font><font style="text-decoration:underline;">RLX3</font><font style="text-decoration:underline;">01 Clinical Data</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported initial data from 14 evaluable patients in dose escalation stage of ongoing Phase 1/2a trial of CRLX301 in solid tumors</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tolerability data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Completed five dosing cohorts in 14 patients with no DLTs</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Highest completed dosing cohort is 75 mg/m<sup style="font-size:85%; vertical-align:top">2</sup><sup style="font-size:85%; vertical-align:top"> </sup>(standard dose for docetaxel) administered once every three weeks</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Opened 90 mg/m<sup style="font-size:85%; vertical-align:top">2</sup> dosing cohort</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Maximum tolerated dose (MTD) has not yet been determined</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investigator-reported activity data:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">One patient with B-RAF mutant carcinoma of unknown origin who previously failed prior B-RAF-directed therapy has experienced tumor shrinkage as measured per CT scans and experienced tumor shrinkage per RECIST with 13% decrease of target lesions and 35% decrease of non-target lesions from baseline</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Next steps:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Continue to enroll patients in dose escalation stage of trial until MTD is determined for (1) once every three weeks dosing and (2) weekly dosing</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Commence Phase 2a portion of trial in H1 2016 and further explore both dosing schedules</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CRLX101 Clinical Development</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Completed enrollment of randomized Phase 2 trial of CRLX101 in combination with Avastin in 3<sup style="font-size:85%; vertical-align:top">rd</sup> and 4<sup style="font-size:85%; vertical-align:top">th</sup> line RCC</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">Data from this trial are expected in H1 2016, and assuming positive data, Cerulean expects to launch a Phase 3 trial in H2 2016 of CRLX101 in combination with Avastin in 3<sup style="font-size:85%; vertical-align:top">rd</sup> and 4<sup style="font-size:85%; vertical-align:top">th</sup> line RCC, an indication for which FDA has granted CRLX101 Fast Track Designation</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Reported first patient dosed in trial of CRLX101 to evaluate weekly dosing schedule</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Courier New;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Courier New;font-size:12pt;"><font style="font-family:Times New Roman;">CRLX101 is dosed every other week at its MTD, and this study will determine whether CRLX101 is tolerable at increased dose intensity, which could increase therapeutic index</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anticipated Upcoming Milestones</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, Cerulean expects to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Report primary and secondary endpoint data (PFS and ORR) from fully enrolled randomized Phase 2 RCC trial of CRLX101 in combination with Avastin during first half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Report results from ongoing Phase 1b trial with GOG Foundation, Inc. of CRLX101 in combination with weekly paclitaxel in relapsed ovarian cancer during first half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Report additional CRLX301 data from Phase 1 trial during first half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Initiate Phase 2a trial of CRLX301 in solid tumors during first half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Report results from ongoing</font><font style="font-weight:bold;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">clinical trial to evaluate weekly dosing schedule with CRLX101 during second half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Report additional interim CRLX101 data from ovarian and rectal ISTs during second half</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:'Symbol';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#183;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:12pt;"><font style="font-family:Times New Roman;">Initiate Phase 3 trial of CRLX101 in combination with Avastin in patients with 3<sup style="font-size:85%; vertical-align:top">rd</sup> and 4<sup style="font-size:85%; vertical-align:top">th</sup> line RCC during second half</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Brief Financial Summary</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2015, Cerulean had cash and cash equivalents of approximately $77.6 million.  Cerulean estimates that its current cash and cash equivalents will fund operations into 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More detailed financial information and analysis may be found in our Quarterly Report on <font style="text-decoration:underline;">Form 10-Q</font>, which was filed with the Securities and Exchange Commission on November 16, 2015.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conference Call Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management will conduct a conference call at 4:30 p.m. (ET) today to provide a business update and review Cerulean&#8217;s third quarter financial results.  The call can be accessed by dialing (844) 831-3031 or (443) 637-1284 prior to the start of the call and referencing conference ID: 49083195.  The conference call will also be webcast live over the Internet and can be accessed on the &#8220;Investors&#8221; section of the Cerulean website, <font style="text-decoration:underline;">www.ceruleanrx.com</font>.  The webcast will be archived on Cerulean&#8217;s website for two weeks.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About CRLX101</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRLX101 is a nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells.&nbsp;&nbsp;CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and also inhibits hypoxia-inducible factor-1&#945; (HIF-1&#945;), which research suggests is a master regulator of cancer cell survival mechanisms.&nbsp;&nbsp;CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments.&nbsp;&nbsp;CRLX101 is in Phase 2 clinical development and has been dosed in more than 300 patients.&nbsp;&nbsp;The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with Avastin in metastatic renal cell carcinoma.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About CRLX301</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells.  In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was similar to or better than docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies.&nbsp;&nbsp;CRLX301 is currently in Phase 1/2a clinical development.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Cerulean Pharma</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cerulean team is committed to improving treatment for people living with cancer.&nbsp;&nbsp;We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body&#8217;s normal cells, and enable therapeutic combinations.&nbsp;&nbsp;Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy.&nbsp;&nbsp;Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit <font style="text-decoration:underline;">www.ceruleanrx.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Cerulean&#8217;s Dynamic Tumor Targeting<font style="font-weight:normal;">&#8482;</font> Platform</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cerulean&#8217;s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments.&nbsp;&nbsp;We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the &#8220;leaky&#8221; vasculature present in tumors but are too large to pass through the wall of healthy blood vessels.&nbsp;&nbsp;Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About GOG Foundation, Inc. (GOG Foundation) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GOG Foundation, Inc. (GOG Foundation) is an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.  The GOG Foundation is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results.  Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care.  The GOG Foundation conducts clinical trials for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva.  The GOG Foundation is a separate entity from the National Clinical Trials Network groups that are funded by the National Cancer Institute.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note on Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about our estimated research and development expenses and sufficiency of cash to fund specified use of cash and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hypothesize,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>

<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the &#8220;Risk Factors&#8221; section of our </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report on </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form 10-</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> filed with the Securities and Exchange Commission on</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> November</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6, 2015,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in other filings that we make with the Securities and Exchange Commission. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We specifically disclaim any obligation to update any forward-looking statements included in this press release</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avastin is a registered trademark of Genentech, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nicole P. Jones</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, Investor Relations and</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Communications</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">njones@ceruleanrx.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617-551-9606</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201511161930512845969.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201511161930512845969.jpg
M_]C_X  02D9)1@ ! @$       #_[@ .061O8F4 9      !_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @("
M @(" @(# P,# P,# P,#_]L 0P$! 0$! 0$" 0$" @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@
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MDK+"<Q1@8J+2(R3QXD-3@S05,$0&_\0 *A,!  $# @8" P # 0$      1$
M(3%!41 @\&%Q@9&A,+'!8-'A\4#_V@ , P$  A #$    ;_
M                    ",TIC-5]LU9?3GV^0
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M:.EU?V)4AIO>\/L+%>CR,@\72VE'9=#:TJ-U]VHW:EG;7_\ ;\_L
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M_P#(LE5_R+)5?\BR53JTN3&OQ3*>D)U63_KNNU33+>/BY_&#2C"#*P-]KZY
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MCY(]Y5BCH#0RE)F4%)]X,F/Z="L-O;@957B<JA_ XF5!B<Z2Z2#TY*OU_@D
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MW[J[RZM\DA_2D'DERM.069;,%X(\DG9T2(H.N!Q!1!DNMJ51[6/B6)\\VO\
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M/3L)E3N^F$<E(C8U.3:3R^D&:(E26,@H^/:0#1-I<DS0=P>^^W/3^=?5<N<
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MBA8@ZCE7VW3F8C,YHHT>/);=-9<1V,*H3G1Z*N5Y(L1N2U NMME=8M\YULG
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MG=!<)J;5KDH[8X?&_"G'.N7DD[T14NFU;T]LE*CT6^V(-- +;;8B#;8"@
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M-#N51"ABN/:!]/X^ZG0W3;NA3VHK)02:I(PNN2Y* C8M2W/H-5G$FIR9(73
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M^J''^C]/^W^)?__:  P# 0 "$0,1   0
M      @                                  &,# "8 "F@'VV0C8 60
M&8N0%VV0 N( FH F  P?7&QW &21 224$2] 6 5"0 B26 $7 #5@$@  *X!\
M[ S;;0R4_P")\N L J$@!$OZ NA &D ) !F0 %ZR!*0!2$F !$,@%@%0D (H
M  (@@ TOA( &RP!=PP.    EFZ)J]@L J$@!$FP!X4P&O.Y  %L '1D>L
M$BDA$CP%@%0D (DDP\@B UHO( %P0  $!2F  0DP (-**L.B$@!%  *N^H&L
MOE  8H  !P0TF)S$MLA%4PD T0E-XELA&VVPUA,H !57@ 5L-4TD>DDH(BXP
M%UF$DG$DM5P 5VL!5  ,F^N3. &TM( VWAD R*H>!6W0VVBX (QV@'H  ](1
M._                                 PS<5@
M             "4                                        !_]H
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M20Q_\"5VTU+;D#F%[@#M(02_'ER_U]XO;Q!(9H:4FW5TA"<D!N%5UKFA( 3
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ME%8H\R2K>-*301Y<<IN\=H:EKZ%:12@"0372G 'O*3(>D)A*3\*>)6X+@DS
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MHU1B!6V 3?)J@R7#^Z MP']#78>!\W<0(*<B.&M0?!43JPS=/^B*NWQX,KP
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M![; T7D:G"SD].Z5V['94FYP] P,Z>:,.G$=;V<2T-AJ$6<B91= EPJ>LYA
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M0.L"\!;#RN'NC +"0L$H.2 3&;B=^\<!8,=C)#$Q")B<DDX6F0&,!)O9&"?
MN3BG))9G0&1BLL(0H* <1'@(N F=4XQMR:ZZO0J(0LC=K>DIV&# :V+ROMRZ
MZZZ_5L &-%V9W*B84F1 R3$KVL7#6UK",R,&["/8<BB  85I3:8;EI'#6^\,
M:CIJ2,Z([%+S2H ) MA8UX:_5L &-%V9W.*VBPT2234<)9$1%*T6/; R7NF)
MO$3>K4]#\C2%[B"-4Y1$2:A$T=PE$H012EXO_;0,IELLG'*AA>XF%LFN0H6$
M$&G+&6+<98'> E NV: 6-V3Q%RF+<S#,T' M65\P/@*0Y$16.P[Z0>\6J:,H
M<J85 =D[4LD$-PO8+=UP9%/-'T!RH7>1V)1:T4@04$H2JJJK*W?\"#&]0<R(
M '"(E"7$ ()HX%JT1J%-,),#T&A,Q3T!2$21-D<UW R_Y1KO)(?R#K41; A;
ML7*<0,/4 T*5U-)'<0=3:8+1$BIE7*[O^"@G0LB61,(Z)083P@_!#.@:;%2=
M;A8[.PRW9EUK*UJ92K@-?I!@#_$O_]H " $# P$_$/\  W&2E((FHN1C7Q7B
MDW, EL5-/).P_P ' "BW=%"N:)(*!J(3IF.U"D(4>8.B!Y+AS>1,!;F8F8H<
MOA(-$-'4$U95HV;>&\G]?MR&@L80*@A;B(0)$FU" 046>5:^H2">\'[%(VK!
M5J($;.@!+V"9MFC#@I$N(X1U'BO-XD038E4+MCEP8,&!(Z(4T=F3'!<>&$01
M-&@EB2A)6=!'X'D BDJ &ZL![X8-+)P69B9,3#$YAVY,%M%3*H,L)8OG@(@)
M1?8S$B8F\<, $4D00W$D?7%_GT@&EU@+VORX,&#!I9."S,3)B88G,.W()?&!
M)7,"@F!8[<,%XI1"D,DI+<AX$E0 #*K8#=X8!%$78V<3)CWR+CPPB")HT"R*
MA<@5@$L KV%Y7#@I5L 95T"G;!35TM<J#=%Y%+@-')0+)F4+]VT;$E0[&0:1
M#2+K4>"][6,*KA5C,!0_9A0"9<BC$$@D!EI;/'<KK_GW4 :%!8NT8L(7! H+
M>RX*S#+<%!!9N17)81-& I96,!*"(62P"Q?D  $#) $!^WR*@&"Y,;J" +<2
M3I1YJDC)((DX0I*1NEA6+9CYYI7P.0N/DIWTS"</80PTF@EDRQN7W8AH%/QD
MV$!MI3%#R_8*4O-JP"XJH+WA)MG _<?B#-5/J/R!,]& QJ$#HQQ=$>$-J( [
MD!YM!LXR\G4]_!MUBV4K)NK@JSAD&T* R(DB)9$N)D_"@<G38-A-<@E3"9 5
MRTI#Y)G,7$T5D-(.(^Q2 I8BP@(!<\D87-<V*V +1<5)1A81Z#_1>U&U)QW4
MFP9->2\9$J?&]8#  74@ J %2GHR,NMI"+) #!@@T$2O5R[.9JEL$  #@  V
M2Y1B=8Q>UD&X_1P<P& 0    "HZRG4=@VRN E4!:9& 8P=E8&WT2@3-YCX_H
MJ'A%C$]L [22<@O2HJ)""&[.FE$R3(E&(<"K:0-UT1%YJ"XRX8TXC@9 1X@F
MGKS=$B1H@&9D;8XBBL%6K82AF3.T\4!=NAJ)7(7N$%%JT%BY=K0]OY34!,@N
MH&LD/<1 !!.Y9:)).XX&$4;-&)!YL-/13[C\09JI]1RA,@JU>6X(T1O'$47J
MUS))C$3AF+<9$A?NE'>" U;%*W.QPM!VE!H <)B8,#_:R LPPPQ1L D+B)(C
MJ)<X]3W\1NQ"&*\CG"[T N\Z!R?E,>$B;C"P7%H5NRC): (%K6! U!C Y%6N
MM=P!(35YN=4:>PY9,8HXE6.[$PK%B5]F&U2O8S!82N)!\)-"LU9M*696 %27
M"PL%60&55NJRH45%5I0I(9B53M-PC<$B7"<%$-)QY5B[&CH*  )5; !=5P41
M-:H60,VFK'*J@\@I%X%M'FA["RB@/D6@=0)7=%;K$OR2?Q 3E&4=LB&=08W9
M8,/ HA>^TMFH_P"YK[C\09JI]1^,)L6B+$9&.^2!I!T>%XX*%AAN2>Z"&>%]
MY]^,?!.77BNI[^*+C&T2;FHX#8*-FHPA0&8A/K%Q6[K'.@<B@HPS%/8T7R,0
M3&5/4M:0Z0V][-T0S"E.81,,3C<LV:F YD0QZ0569N!@')$@ FZ Y0-!-S$R
M:F6)=0+3<$31;8:*@5KF,L"@B7F!$<A>+P[#(>P5FC%#81PQB(<D%@*QN#B?
M-5*Y57[:M7AHF\RVLU?:,I^(FT7Y%! *"%0"8F -#C=NBI6309(+4)T.*!:"
M5%$TR[+%3"$9F_5^J$MX,Q@P&@: #0I-0X8D_8EVAUHT8&]B%\!7W'X@S53Z
MCE";L%D&*6E"%C5XW;O]+8X%$P3$3!.#C?(?9AH&C*A,Y$"@)G:X2D]B970%
MHDB$CJ(:,JABXEF:3 XV4*.XB-2T+6K$C^R#N./4]_#.XZT2XZ%OA)%3112N
MA)0:(B-,;QKFRG[:F^P4*$ @HL\R!RS\:%KX."26I3,B4H  BEU18>!0\M=_
MJ4_P!MI@M1/PV,1?C-RT6>10(N7*27(D;1FKA1,) D* 81(RS% !U?AI(03:
M=9[HZ$0R-VV/E,]K7&'=DTV@O3?;WH!>)[-ZN]_JAE1#)GZR:G/E*B(T+"-D
M3(E&UCNXC^]>OQ$U.-949D$MQ,1>-'B3)CNMY(166A?1XH%48$H%@$JQH JX
M"[PB@B@8*" *DEAS*B4;JQ1P4S?-RZ2@$@.#[C\09JI]1RA,>]WA$2$$MM3B
M3)^5D"ULT1J1,VP\$,!7>T+6 S<QFE4HJ;M70)HXB9&\<S1?;A;"@(+$1'=?
M*KV:FTR>@-:6:MR7>\S[CPZGOXGJ'A&&WLVP7S*<,B+TKE =UG<JUEYD#AFQ
MW8#T;+U.M!LB";PO"8R"C2XUG2",O9/W]%;LP'!'TW'/L[IH@'G24Y# "55L
M $KH44H&YSK.4O*"Z@"U-?7.Z&A+._4':ES"&-,3-J[-XO-PW5%B ]R7VJAT
M4:3($W<$TEO5PV!P(0[(CR@2A)2VXPGI$=FWXB?Q 'I]K@!#411[4+2$EOUS
MJW*06UJP!>&!KKNUUADO1E6SV$P[)(9!&YPS*C^H+Z'D-S26,W@7@Y!1#V()
M^4/?)4^H_$$V-,*0[S-F4'1+:TQ>#@!8BLJP'@*_]BAV:A@R2%(!) G>#8X:
M;@5UX(;'+N.'4]_$[\AS@2)V1BC@14:QN<>/L@$B)OS:,60M*D)NDJ7I+DF)
MH3!,3$P3MRN3H.T4@)[%:1OFQRV&6 IIHCLHTP(*H3##C ;%M220.*$@Y%38
M'*Z5$GG9)<SU=N,(@DBYE *TG"BG8!ZI1)?J$I22&)(N*U/5  7)78T%.WN<
M#%&BU,Y*O$LDHW&X3T08 '8%]P -D'@+MY$-NH![:>S28*0U"PRQ 905H-7#
M9RDERJF4[RB2TA0^L )$+(EQ.)-K]45I!,(8D2<2.W'!@2.B%-'9DQR("=]H
M(0N\>2TV@0GAM]Q/R/Z/-TX'=)1_U@0G?@PHN@*(-@ $6&,)*NKGTGV^O3K6
M)0&@",Q=)%/*/X>2H,2F1)-P6NJO[3Z-F8&/AXDVO1 ZFHD3QP8-+)P69B9,
M3#$YAVH%3:8 J>P"M2!6@Y#IPM0)"4.74=""3Y*_\BC_ ,BC_P BB E,6( 3
MY0G9KTQ$YQ[>Y.<<.I[^0S_$RH)C=7 @K@%[07:-((1&$1N(V1P\SD,?0 5+
M+8;UH)FD (&$<C3L!3V%.,K"WEG*+UPF*S<:# 5&1@4?L>1F@!D$^1O=3#@I
M$N(X1U'D2HV(E%PI&1-B4"(X))%"#"&6@Q1,_P"<3JY"S0C+I95T@O"$(<TV
M0DC@>5KI A#411I6R49D8U(%R@ (<-%1/'SPC]U&WGM^2?M10B;,-XFC:T6M
MP&H"#,-SM9T.!F2B;%DD54-5*@ 6 $!^$FP@)HC%D(W$<B4YHONDK,][;F"8
M5*ALZ2IA-0D,*1LTP=O#4K-V*Z226C@IB$9=2G05,=A+@*.@\0HV%@[$':LG
M43/E5>V@LD 4$ $JJP!=:2&W00R@"DB7B*+)A/RU&"9Z*1F3-[B9^/#7RPFL
M"W/$+Y->!1B^[WU;$&O#S_",1)WEJ]3W\IPD8HBS6B,&;M%6SS.1.A&141DR
MN#" IHC%9;("F,D$M20A(BV0BYEV74!05OXY10ZC#$24C":QFCA)NAJD"MV6
MBL%W2GLX#Y1LZ(3222ME'L,9$EX-J;*1#&W:$4MQ5I2\CL-R/ZLF),/.=1X\
MH0PB&5F-@E;$Q5,P(*&64E:D'( !A(@(B0B-D2R-DI]P*S)[-4NR6*,[LLLI
MW(QW)&RTDJ<=%^R+Y*-R)DC[KZH03AC3>X6A%PW!4)J@X3   -@X%^[&HD9"
M]P@Y6&&& [[4@6#P#7CC(#0?$TS]L>H&%M99>$JV_ 0$*\ 6>E/!@#NT5!$<
M(1)I(%W :(P.3LCG(0)=#3ITR(DV4[-H93EQW, DQ,GU88R%$CE)11:XDWR+
M,9H2R.(Q(0DC>2+5%!1XE:+S: D:(SG?D888#M]&%<- O5"7(87Q"V_*PPPQ
M]E' )U3&(V:D_GU2$PQ.BTX3%RF6X@)<W=>ZY"H&B2%0B\6L7@<&+8-2J:.A
M"1_L46D2"B8%"Z$Z<&/LHX!.J8Q&SQ.2J6H0PZ)E%T"0A6L_[R:%K(F+3BU7
M:/SX%A;62O8>5FK1Y$PFJ@CED @0PX),S# !8$*UT[S@@W6AK%65"(WX$A&+
MG5$2@Q8(IIC,-<S97F2$21%*'#4@\>0NJOP6$:9R[21"9%O4"2PP(7-.(E:R
MS3R@-E[AELNL"0*CUR[#R2% 8;!#)4F&^\.        1_@3HT'PH'J"R"-2_
M*3@Y3)=!.QP0QP"'?\W1))": ,*1%$3")<>Y7_@@4 /JO>CF(FZ-#30J7^!!
MOLX0S!,FS4%>% 5 [8YD=^2%#!@H L 8 T#_  5.8!$21&R(V1+(YI>U,I8P
B[%M5KNSG(EA6[O<;V+#0(*BRK$:@ N>GWERJ_P"(_P#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
